Moderna Q2 2026 Revenue $145M with $0.8B GAAP Net Loss
Moderna reported $145 million in Q2 2026 revenue despite a $0.8 billion GAAP net loss, improved expense outlook, and halted enrollment for a norovirus vaccine due to trial setbacks.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day